Morgan Stanley Initiates Coverage on Pharmasset (VRUS)
More News related to VRUS
- Pharmasset to Present at Lazard Capital Markets Healthcare Conference
- InterMune (ITMN) Higher Following INFORM-1 Trial Data
- Baird Maintains an 'Outperform' on Pharmasset (VRUS); Year Ahead is Catalyst-Rich
- INFORM-1 Results: Robust Antiviral Suppression Achieved with Combination of Nucleoside Analog Polymerase Inhibitor RG7128 and Protease Inhibitor RG7227
- INFORM-1 Results: Robust Antiviral Suppression Achieved with Combination of Nucleoside Analog Polymerase Inhibitor RG7128 and Protease Inhibitor RG7227
More News related to New Coverage
- Morgan Stanley Initiates Coverage on Williams Companies (WMB) with an Overweight
- Morgan Stanley Starts ONEOK (OKE) at Underweight, $40 Price Target
- Broadpoint.Amtech Initiates Coverage on Willbros Group (WG) with a Buy; Leading North American Pipeline Contractor
- Miller Tabak Initiates Coverage on Oclaro (OCLR) with a Buy
- Natixis Bleichroeder Initiates Coverage on Gen-Probe (GPRO) with a Buy
Morgan Stanley initiates coverage on Pharmasset (Nasdaq: VRUS) with an Equalweight.
Pharmasset, Inc. (Pharmasset) is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections.
Related Categories
New CoverageStocks Mentioned
+0.96Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
